Experience

Link Cell Therapies

• United States
• Biotechnology Research
• 1 - 100 Employee

• Scientist

  • Jan 2023 - Present



Senti Biosciences

• United States
• Biotechnology Research
• 1 - 100 Employee

• Scientist

  • Apr 2021 - Apr 2022

  CAR-NK cell therapy-synthetic biology-gene circuits. Development of synthetic receptors. IL-15 CAR-NK cell therapy-synthetic biology-gene circuits. Development of synthetic receptors. IL-15



Recursion

• United States
• Biotechnology Research
• 300 - 400 Employee

• Senior Associate

  • Oct 2020 - Apr 2021

  Immunology, IL-15 Immunology, IL-15



Miltenyi Biotec

• Germany
• Biotechnology Research
• 700 & Above Employee

• Scientist I

  • Sep 2019 - Oct 2020

  CAR T cell enhancement Development of synthetic receptors. IL-15 CAR T cell enhancement Development of synthetic receptors. IL-15



FDA

• United States
• Government Administration
• 700 & Above Employee

• FDA/ORISE

  • Jun 2018 - Sep 2019

  Aim: Elucidate potential therapeutic effects of OT-1/mb-IL15 against solid tumor in lymphoreplete mice. Role: Performed transduction of murine CD8+ OT-1 cells with mb-IL15 molecular construct. Performed adoptive cell transfers of CD8+ OT-1 expressing mb-IL15 to C57BL/6J mice. Designed flow cytometry panels using 8-10 colors. Utilized BD LSRII and LSRFortessa flow cytometers. Handled mice and performed IV and IP injections. Performed tail nick and cardiac puncture for blood collection. Immunostaining of splenocytes and whole blood. Used FlowJo, GraphPad Prism, and BD FACSDIVA software Show less



National Cancer Institute (NCI)

• United States
• Research Services
• 700 & Above Employee

• Cancer Research Training Award Fellow

  • Jun 2016 - Jun 2018

  Aim: Engineer TCR/CAR T cells with IL-15 to generate synergistic effects between host immune cells and TCR/CAR T cells against solid tumors and enhance expansion of TCR/CAR T cells in lymphoreplete mice. Role: Designed and developed mbIL-15 molecular constructs using In-fusion cloning technique and SnapGene software. Subcloned molecular construct to retroviral expression vector. Performed transfections for retrovirus production. Executed Isolation, activation and transduction of murine CD8a T cells. Utilized flow cytometry BD FACSCalibur and FlowJo to measure transduction efficiency of CAR and mb-IL15 molecular constructs. Executed intracellular staining to detect IL-15 signaling. Performed flow cytometry-based killing assays. Designed and executed experiments to block IL15 signaling using mABs Show less



Intrexon Corporation

• United States
• Biotechnology
• 1 - 100 Employee

• Research Associate

  • Aug 2015 - Nov 2015

  Aim: Execute cell-based assays using proprietary CAR T technology to assess their anti-tumor immunity and safety switch. Role: Performed antibody-dependent cellular cytotoxicity (ADCC) assays, complementdependent cytotoxicity (CDC) assays and killing assays. Analyze cell-based assays using iQue flow cytometer and FlowJo software. Isolation of PBMCs from leukopaks. Aim: Execute cell-based assays using proprietary CAR T technology to assess their anti-tumor immunity and safety switch. Role: Performed antibody-dependent cellular cytotoxicity (ADCC) assays, complementdependent cytotoxicity (CDC) assays and killing assays. Analyze cell-based assays using iQue flow cytometer and FlowJo software. Isolation of PBMCs from leukopaks.